Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) A 26-week double-blind study

Overview of attention for article published in Diabetes Care, January 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news: 1 news outlet
policy: 1 policy source
twitter: 5 X users

patent: 2 patents
facebook: 1 Facebook page
guideline: 1 clinical guideline source

Readers on

mendeley: 247 Mendeley
citeulike: 2 CiteULike

So far, Altmetric has seen 7 X posts from 5 X users, with an upper bound of 10,028 followers.

Exenatide Once Weekly Versus Metformin, Pioglitazone & Sitagliptin Used as Monotherapy in Drug-Naive Patients With T2DM http://t.co/iDtAxRQ4

Ill give GLP1 analoges high five ; treats diabetes and reduces weight !! SOURCE: http://t.co/pJF2LOfP

Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as… The #Pillbook14 p.465,692,533,1040 http://t.co/ZDcHm80L

Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as… The #Pillbook14 p.465,692,533,1040 http://t.co/Se9xIui7

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 3 additional X posts.